61.08 USD
▲+1.59+2.67%
盘后 61.40 +0.52%
2026-09-15
市值
$2.97B
市盈率
—
EPS
-2.40
股息率
—
52 周区间
9.64 – 72.64
成交量
652.59K
Beta
0.04
目标价
88.36
52W 低 9.6452W 高 72.64
价格走势
公司简介
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy fo...